about
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment...
Read More
190.96
-3.43
(-1.76%)
2.2M
XNAS Volume
XNAS 13 Nov, 2025 4:30 PM (EST)
Board Meeting
The next board meeting for Insmed Inc is on 18 Nov 2025 for the purpose of Jefferies Global Healthcare Conference
See details
Low Financial Strength
Expensive Valuation
Technically Bullish
Momentum Trap
These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked.
View Similar
Embed DVM
Insmed Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..